Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Obook Holdings CEO Chun Kai Wang Buys $13.4K of Stock
Chun Kai Wang, CEO, bought 6,171 shares of Obook Holdings Inc. at $2.17 a share, worth $13.4K in total on Nov 12, 2026. Shares held after the trade: 3,157,147 (+0.2%).
Contango Silver & Gold Inc. reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $12.0 million loss in the prior year, driven by increased exploration and general administrative expenses. Total assets grew significantly to $492.8 million following the Dolly Varden acquisition, which added substantial mineral property and equipment value.
SBC Medical Group reported third quarter 2026 revenue of $59 million, a 35% increase year-over-year, driven by service fee revisions and clinic network expansion. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA grew 66% to $28 million. The company's supported clinic network expanded to 293 locations, representing a year-over-year increase of 36 locations.
Term
Q3 2026
“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA margin of 47%.”
Yoshiyuki Aikawa, Chairman and CEO
“Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”
Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.
Nova Minerals reported operational progress for the quarter ended September 30, 2026, including the receipt of $23.9 million to date from a $43.4 million Department of War award. The company secured final permits from the Alaska Department of Natural Resources for its pilot-scale antimony development and is advancing towards a 2027 production target at the Estelle Gold and Critical Minerals Project.
Vertiv Holdings Co announced that its Board of Directors has raised its regular annual cash dividend by 60%, from $0.25 to $0.40 per share. The increase begins with a fourth-quarter dividend of $0.10 per share, payable on December 17, 2026, to shareholders of record as of November 24, 2026.
Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism. The study met its primary efficacy endpoint with 13 of 16 participants achieving at least a 50% reduction in glucose infusion rate, including 12 who completely discontinued IV glucose. The company expects to report full topline results in mid-December 2026 and engage with the FDA in Q1 2027.
Regional Health Properties reported a net loss of $2.9 million for the nine months ended September 30, 2026, compared to a net income of $0.7 million in the prior year period. While total revenues grew significantly to $70.6 million due to increased patient care and pharmacy revenues, the company faced higher operating expenses and an impairment loss on assets held for sale.
Ziyu Shen, CEO, bought 300,000 shares of Ecarx Holdings Inc. at $0.7789 a share, worth $234K in total on Nov 11, 2026. Shares held after the trade: 300,000.
Blue Biofuels, Inc. reported a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a loss of $1,587,132 in the prior year period. The company remains in the development stage with zero revenue, while operating expenses increased due to higher research and development costs and stock-based compensation.
First Choice Healthcare Solutions reported a significant net loss of $19.1 million for the nine months ended September 30, 2026, primarily driven by $17.4 million in interest expense. The company is currently pivoting its strategy toward a network of nurse practitioner-driven primary care clinics despite having zero revenue in the current period.
OpenWorld, Inc. reported a significant net loss of $16.1 million for the nine months ended September 30, 2026, compared to a net income of $1.0 million in the prior year, primarily driven by a decrease in total revenues and a sharp increase in general and administrative expenses. The period was marked by a reverse acquisition of VerifyMe, Inc. and substantial non-cash stock-based compensation and professional fees totaling over $12 million.
Weatherford International completed its redomestication from Ireland to Delaware via a scheme of arrangement, with Weatherford International Corp (US) becoming the new publicly traded parent company. Shareholders received shares in the new Delaware entity on a one-for-one basis, and the company expects to generate $20 million to $30 million in annual cash savings starting in 2027. The move simplifies the corporate structure without changing business operations, management, or strategy.
Nektar Therapeutics reaffirmed its financial guidance, stating that its current cash and marketable securities balance of $952.9 million is expected to fund operations into the third quarter of 2028. This runway is intended to support the company through the initial Phase 3 data readouts for its ZENITH AD trials in atopic dermatitis, expected in the summer of 2028.
iRhythm Holdings adopted a new nonqualified Deferred Compensation Plan effective January 1, 2027, for eligible employees and non-employee directors. The plan allows participants, including named executive officers, to defer up to 80% of base salary and 100% of annual bonuses or cash fees into notionally invested accounts. While the plan is unfunded, the company intends to establish a trust to hold assets for these future obligations.
Hyperion DeFi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $79.4 million compared to a net loss of $5.5 million in the prior year, primarily driven by $93.6 million in realized and unrealized gains on digital assets. Total assets grew to $146.3 million from $51.8 million at year-end 2025, reflecting substantial appreciation in the company's digital asset holdings.
King Resources Global, Inc. is a Nevada holding company operating through subsidiaries in Hong Kong and the British Virgin Islands. The company reported 112,616,649 shares of common stock outstanding as of October 21, 2026, and is currently navigating significant regulatory risks related to PRC oversight and the Holding Foreign Companies Accountable Act.
AIRO Group Holdings entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market (ATM) offering program. Under the agreement, the company may issue and sell shares of its common stock from time to time at its sole discretion. AIRO will pay the agent a commission of 3.0% of the gross sales proceeds from any shares sold under the program.
Presidio Production Company reported Q3 2026 financial results, featuring a 15% increase in net production to 26.1 MBoe/d following the acquisition of Canyon Creek. The company reported total revenue of $57.3 million and Adjusted EBITDA of $29.1 million, while declaring an increased quarterly dividend of $0.375 per share.
Term
Q3 2026
“Our third quarter results reflect continued execution of our acquisition and optimization strategy. Canyon Creek contributed its first full quarter, and our continued focus on improving the performance of our existing assets has allowed us to increase our annualized dividend to $1.50 per share. Each of these steps reinforces the acquisition model we are building to consolidate producing oil and gas assets.”
Will Ulrich, Chairman and Co-CEO
“When we closed Canyon Creek, we said the Arkoma Basin was a place to build scale through consolidation. In our first full quarter operating the assets, we moved the wells onto our production systems, right-sized compression and changed chemical vendors, and Canyon Creek helped lower our lease operating expense per Boe.”
TCW Specialty Lending IX LLC is a newly formed business development company that has not yet commenced investment operations as of September 30, 2026. The company reported total assets of $484,830, primarily consisting of receivables from its investment adviser for organizational and offering costs, with a net asset value of $1,000. All operating expenses incurred since inception have been reimbursed by the Investment Adviser, resulting in zero net investment income.
TCW Star Direct Lending LLC reported total investments at fair value of approximately $238 million as of September 30, 2026, with a portfolio primarily consisting of senior secured debt. The company maintains a diversified industry exposure, with significant concentrations in Food Products, Hotels, Restaurants & Leisure, and Personal Care Products.
TCW Specialty Lending LLC is a newly formed business development company that commenced operations on March 2, 2026. As of September 30, 2026, the company held a diversified portfolio of debt investments across various industries, with its largest exposures in Electrical Equipment (14.9% of net assets) and Building Products (12.1% of net assets).
TCW Steel City Senior Lending BDC reported total investments of $791.4 million as of September 30, 2026, with a portfolio primarily focused on debt investments across various industries including Building Products and Professional Services. The company maintains a significant position in short-term U.S. Treasury Bills and reported 19,659,875 common shares outstanding.
TCW Direct Lending VII LLC reported total investments of $1.16 billion at fair value as of September 30, 2026, with a significant concentration in debt investments across industries like Textiles, Apparel & Luxury Goods and Hotels, Restaurants & Leisure. The company's net assets stood at $400.2 million, supported by 13,734,010 common units outstanding.
TCW Direct Lending VIII LLC reported a diverse portfolio of debt investments across industries such as automobile components, commercial services, and food products as of September 30, 2026. The company held 6,310,260 common units outstanding and maintained significant positions in term loans with varying SOFR-based interest rates and PIK components.
For the nine months ended September 30, 2026, TCW Direct Lending Strategic Ventures LLC reported a net decrease in members' capital from operations of $8.4 million, compared to a $4.2 million decrease in the prior year period. The decline was primarily driven by $9.7 million in net unrealized depreciation on affiliated investments, specifically related to SSI Parent, LLC common and preferred stock.
Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.
Bio Essence Corp. reported a net income of $324,992 for the nine months ended September 30, 2026, a significant improvement from a net loss of $132,890 in the prior year period. Despite this profitability, the company maintains a working capital deficit of $1,374,178 and an accumulated deficit of over $9.2 million, leading management to express substantial doubt about its ability to continue as a going concern.
Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.
Term
Q3 2026
“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
SoundHound AI, Inc. filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its completed merger with LivePerson, Inc. The filing includes audited and unaudited financial data for LivePerson and combined pro forma financials to help investors assess the impact of the acquisition.